Please login to the form below

Not currently logged in
Email:
Password:

Pharma must step up monitoring of social media

New service intends to help keep track of online patient communications

Social media has been a rising point of concern for pharma companies with regards to the monitoring of patient communications about drug safety, but a new service could help track online activities.

Patient reports have been notoriously hard to rack on tools such as Facebook and Twitter, leading to such regulatory concerns such as Roche last year, with the Swiss pharma company found to have “serious shortcomings” with regards to pharmacovigilance practices following an investigation by the European Medicines Agency (EMA).

Life sciences consulting company YourEncore says its new service to track social media communications – which evolved from previous work with a pharma company - could help avert future regulatory breaches such as those committed by Roche.

“Drug makers may have hundreds of patient outreach programmes worldwide gathering patient safety information every day without the required regulatory controls,” said Pam Holland, YourEncore's managing director, life sciences.

“We help ensure that all past and future safety information is handled according to the law.”

The service was developed after YourEncore experts visit an unnamed pharma firm's operations across more than 20 countries, reviewing its patient outreach programmes in order to identify shortcomings and enhance reporting standards.

Regulatory agencies are also doing more to help pharma companies comply with the pharmacovigilance rules amid the rise of online technologies.

This includes the publication at the start of the year of draft FDA guidance on 'interactive promotional media', encompassing Twitter, Facebook and blogs.

Article by
Tara Craig

2nd April 2014

From: Marketing, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics